{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:25:04Z","timestamp":1778462704679,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00dcB\u0130TAK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jpba.2024.116085","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:31:42Z","timestamp":1709695902000},"page":"116085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Impurity assessment, development and validation of an RP-HPLC method for the determination of eleven potential impurities of eltrombopag precursor"],"prefix":"10.1016","volume":"243","author":[{"given":"Timur","family":"Demirhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Guksu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u00fccel","family":"Yazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esen","family":"Bellur Atici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel A.","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpba.2024.116085_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MJT.0b013e318199d6b7","article-title":"Eltrombopag (Promacta), A thrombopoetin receptor agonist for the treatment of thrombocytopenia: current and future considerations","volume":"17","author":"Serebruany","year":"2010","journal-title":"Am. J. Ther."},{"issue":"4","key":"10.1016\/j.jpba.2024.116085_bib2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/bloodadvances.2017010660","article-title":"Eltrombopag for use in children with immune thrombocytopenia","volume":"2","author":"Kim","year":"2018","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.jpba.2024.116085_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: Efficacy review and update on drug safety","volume":"9","author":"Gonzalez-Porras","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"issue":"9","key":"10.1016\/j.jpba.2024.116085_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.111.040170","article-title":"Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects","volume":"39","author":"Deng","year":"2011","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.jpba.2024.116085_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s00535-012-0600-5","article-title":"Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study","volume":"47","author":"Kawaguchi","year":"2012","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jpba.2024.116085_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpha.2015.02.001","article-title":"Identification, synthesis and characterization of process related impurities of benidipine hydrochloride, stress-testing \/ stability studies and HPLC\/UPLC method validations","volume":"5","author":"Bellur Atici","year":"2015","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113145","article-title":"Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods","volume":"183","author":"Bellur Atici","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115845","article-title":"Investigation of aclidinium bromide degradation by stability-indicating HPLC methods, characterization of impurities by NMR, and identification of degradation products by LC-MS","volume":"238","author":"Yazar","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115861","article-title":"Comprehensive UHPLC\u2013MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation","volume":"238","author":"Jire\u0161","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114972","article-title":"Kinetic and mechanism study of the spontaneous, solvent- and base-catalyzed degradation of the precursor of the \u03b2-nitro alcohol metaraminol by combining HPLC\/electronic circular dichroism\/theoretical methods","volume":"220","author":"Cantatore","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114684","article-title":"Development and validation of ion-pairing HPLC-CAD chromatography for measurement of Islatravir\u2019s phosphorylated intermediates","volume":"213","author":"Gunsch","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.jpba.2024.116085_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5316","article-title":"Synthesis, characterization and control of eight process-related and two genotoxic fingolimod impurities by a validated RP-UPLC method","volume":"36","author":"Bellur Atici","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2024.116085_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpba.2019.05.053","article-title":"Determination of epoxide impurity in sarpogrelate hydrochloride intermediate by UHPLC and column-switching liquid chromatography","volume":"174","author":"Wang","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"10","key":"10.1016\/j.jpba.2024.116085_bib14","first-page":"1800","article-title":"Development and validation of chiral HPLC method for quantification of 3-(S)-quinuclidinol in pharmaceutically important precursor, 3-(R)-quinuclidinol, by precolumn derivatization","volume":"54","author":"Gaykar","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2024.116085_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2014.04.024","article-title":"Isolation and structure characterization of related impurities in etimicin intermediate P1 by LC\/ESI\u2013MSn and NMR","volume":"97","author":"Wang","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1358\/dof.2006.031.09.1030939","article-title":"Eltrombopag","volume":"31","author":"Revill","year":"2006","journal-title":"Drugs Future"},{"key":"10.1016\/j.jpba.2024.116085_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.14233\/ajchem.2021.22951","article-title":"Synthesis and characterization of potential impurities of eltrombopag olamine","volume":"33","author":"Srinivasachary","year":"2020","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.jpba.2024.116085_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpba.2014.04.028","article-title":"Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50 \u03bcL of human plasma: a pharmacokinetic study","volume":"98","author":"Maddela","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.18596\/jotcsa.724484","article-title":"Stability indicating analytical method development and validation of eltrombopag olamine in tablet dosage form by RP-UPLC","volume":"7","author":"Patel","year":"2020","journal-title":"J. Turk. Chem. Soc. A: Chem."},{"key":"10.1016\/j.jpba.2024.116085_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.13005\/ojc\/340262","article-title":"Stability indicating UHPLC method development and validation for estimation of eltrombopag and its related impurities in tablet dosage form","volume":"34","author":"Mohan","year":"2018","journal-title":"Orient. J. Chem."},{"key":"10.1016\/j.jpba.2024.116085_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114231","article-title":"QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction","volume":"203","author":"Jayagopal","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116085_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jaoacint\/qsac153","article-title":"Stability-indicating RP-HPLC method development and validation for eltrombopag olamine in the presence of impurities and degradation products. Robustness by design of expert software","volume":"106","author":"Dandabattina","year":"2023","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.jpba.2024.116085_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/bios13030300","article-title":"Elucidation of DNA-eltrombopag binding: Electrochemical, spectroscopic and molecular docking techniques","volume":"13","author":"Cheraghi","year":"2023","journal-title":"Biosensors"},{"key":"10.1016\/j.jpba.2024.116085_bib24","unstructured":"ICH Guideline Q2 (R1), Step 5, Validation of analytical procedures: Text and methodology, European Medicines Agency, CPMP\/ICH\/381\/95, June 1995."},{"key":"10.1016\/j.jpba.2024.116085_bib25","unstructured":"ICH Guideline Q3A (R2), Step 5, Impurities in new drug substances, European Medicines Agency, CPMP\/ICH\/2737\/99, October 2006."},{"key":"10.1016\/j.jpba.2024.116085_bib26","unstructured":"ICH Guideline Q3B (R2), Step 5, Impurities in new drug products, European Medicines Agency, CPMP\/ICH\/2738\/99, June 2006."},{"key":"10.1016\/j.jpba.2024.116085_bib27","unstructured":"ICH Guideline M7 (R2), Step 5, Guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, European Medicines Agency, EMA\/CHMP\/ICH\/83812\/2013, July 2023."},{"key":"10.1016\/j.jpba.2024.116085_bib28","unstructured":"I.C.H., Q6A Specifications: Test Procedures and Acceptance Criteria, European Medicines Agency, CPMP\/ICH\/2738\/99, May 2000."},{"key":"10.1016\/j.jpba.2024.116085_bib29","unstructured":"ICH Guideline Q1A (R2), Step 5, Stability testing of new drug substances and products validation of analytical procedures: Text and methodology, European Medicines Agency, CPMP\/ICH\/2736\/99, August 2003."},{"key":"10.1016\/j.jpba.2024.116085_bib30","unstructured":"ICH Guideline Q1B, Step 4, Stability testing: Photostability testing of new drug substances and products Q1B, International Conference on Harmonisation, November 1996."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:04:56Z","timestamp":1715285096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0731708524001250"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116085","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impurity assessment, development and validation of an RP-HPLC method for the determination of eleven potential impurities of eltrombopag precursor","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116085"}}